Cargando…

Efficacy and Safety of a High-Energy, Low-Protein Formula Replacement Meal for Pre-Dialysis Chronic Kidney Disease Patients: A Randomized Controlled Trial

High-energy, low-protein formulas (HE-LPFs) are commonly used as oral nutritional supplements (ONSs) to help provide extra calories to patients who are adhering to a low-protein diet (LPD) after diagnosis with chronic kidney disease (CKD). This randomized controlled trial aimed to evaluate the effic...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Wen-Ching, Hsieh, Hui-Min, Chen, Jun-Peng, Tsai, Shang-Feng, Chiu, Hsien-Fu, Chung, Mu-Chi, Huang, Shih-Ting, Chen, Yun-Yu, Chen, Cheng-Hsu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10648072/
https://www.ncbi.nlm.nih.gov/pubmed/37960159
http://dx.doi.org/10.3390/nu15214506
_version_ 1785135253975728128
author Yang, Wen-Ching
Hsieh, Hui-Min
Chen, Jun-Peng
Tsai, Shang-Feng
Chiu, Hsien-Fu
Chung, Mu-Chi
Huang, Shih-Ting
Chen, Yun-Yu
Chen, Cheng-Hsu
author_facet Yang, Wen-Ching
Hsieh, Hui-Min
Chen, Jun-Peng
Tsai, Shang-Feng
Chiu, Hsien-Fu
Chung, Mu-Chi
Huang, Shih-Ting
Chen, Yun-Yu
Chen, Cheng-Hsu
author_sort Yang, Wen-Ching
collection PubMed
description High-energy, low-protein formulas (HE-LPFs) are commonly used as oral nutritional supplements (ONSs) to help provide extra calories to patients who are adhering to a low-protein diet (LPD) after diagnosis with chronic kidney disease (CKD). This randomized controlled trial aimed to evaluate the efficacy and safety of an HE-LPF as either a partial or a total replacement for one meal in pre-dialysis CKD patients. Stage 4–5 CKD patients received either a once-daily HE-LPF (HE-LPF group) or normal food (control group) for a period of 4 weeks while following an LPD. Overall, 73 patients who completed the study were included in the intention-to-treat population. After analyzing the 3-day food records, the HE-LPF group experienced a significant decrease in the percentage of energy derived from protein (p < 0.05) and an increase in the percentage of energy derived from fat (p < 0.05) compared to the control group. The two groups had no significant differences in body weight, body composition, grip strength, renal function, electrolytes, or metabolic markers. The HE-LPF group had a high adherence (94.9% at week 4), and no adverse effects were observed. HE-LPFs are safe to employ as meal replacements for pre-dialysis CKD patients adhering to an LPD.
format Online
Article
Text
id pubmed-10648072
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106480722023-10-24 Efficacy and Safety of a High-Energy, Low-Protein Formula Replacement Meal for Pre-Dialysis Chronic Kidney Disease Patients: A Randomized Controlled Trial Yang, Wen-Ching Hsieh, Hui-Min Chen, Jun-Peng Tsai, Shang-Feng Chiu, Hsien-Fu Chung, Mu-Chi Huang, Shih-Ting Chen, Yun-Yu Chen, Cheng-Hsu Nutrients Article High-energy, low-protein formulas (HE-LPFs) are commonly used as oral nutritional supplements (ONSs) to help provide extra calories to patients who are adhering to a low-protein diet (LPD) after diagnosis with chronic kidney disease (CKD). This randomized controlled trial aimed to evaluate the efficacy and safety of an HE-LPF as either a partial or a total replacement for one meal in pre-dialysis CKD patients. Stage 4–5 CKD patients received either a once-daily HE-LPF (HE-LPF group) or normal food (control group) for a period of 4 weeks while following an LPD. Overall, 73 patients who completed the study were included in the intention-to-treat population. After analyzing the 3-day food records, the HE-LPF group experienced a significant decrease in the percentage of energy derived from protein (p < 0.05) and an increase in the percentage of energy derived from fat (p < 0.05) compared to the control group. The two groups had no significant differences in body weight, body composition, grip strength, renal function, electrolytes, or metabolic markers. The HE-LPF group had a high adherence (94.9% at week 4), and no adverse effects were observed. HE-LPFs are safe to employ as meal replacements for pre-dialysis CKD patients adhering to an LPD. MDPI 2023-10-24 /pmc/articles/PMC10648072/ /pubmed/37960159 http://dx.doi.org/10.3390/nu15214506 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Yang, Wen-Ching
Hsieh, Hui-Min
Chen, Jun-Peng
Tsai, Shang-Feng
Chiu, Hsien-Fu
Chung, Mu-Chi
Huang, Shih-Ting
Chen, Yun-Yu
Chen, Cheng-Hsu
Efficacy and Safety of a High-Energy, Low-Protein Formula Replacement Meal for Pre-Dialysis Chronic Kidney Disease Patients: A Randomized Controlled Trial
title Efficacy and Safety of a High-Energy, Low-Protein Formula Replacement Meal for Pre-Dialysis Chronic Kidney Disease Patients: A Randomized Controlled Trial
title_full Efficacy and Safety of a High-Energy, Low-Protein Formula Replacement Meal for Pre-Dialysis Chronic Kidney Disease Patients: A Randomized Controlled Trial
title_fullStr Efficacy and Safety of a High-Energy, Low-Protein Formula Replacement Meal for Pre-Dialysis Chronic Kidney Disease Patients: A Randomized Controlled Trial
title_full_unstemmed Efficacy and Safety of a High-Energy, Low-Protein Formula Replacement Meal for Pre-Dialysis Chronic Kidney Disease Patients: A Randomized Controlled Trial
title_short Efficacy and Safety of a High-Energy, Low-Protein Formula Replacement Meal for Pre-Dialysis Chronic Kidney Disease Patients: A Randomized Controlled Trial
title_sort efficacy and safety of a high-energy, low-protein formula replacement meal for pre-dialysis chronic kidney disease patients: a randomized controlled trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10648072/
https://www.ncbi.nlm.nih.gov/pubmed/37960159
http://dx.doi.org/10.3390/nu15214506
work_keys_str_mv AT yangwenching efficacyandsafetyofahighenergylowproteinformulareplacementmealforpredialysischronickidneydiseasepatientsarandomizedcontrolledtrial
AT hsiehhuimin efficacyandsafetyofahighenergylowproteinformulareplacementmealforpredialysischronickidneydiseasepatientsarandomizedcontrolledtrial
AT chenjunpeng efficacyandsafetyofahighenergylowproteinformulareplacementmealforpredialysischronickidneydiseasepatientsarandomizedcontrolledtrial
AT tsaishangfeng efficacyandsafetyofahighenergylowproteinformulareplacementmealforpredialysischronickidneydiseasepatientsarandomizedcontrolledtrial
AT chiuhsienfu efficacyandsafetyofahighenergylowproteinformulareplacementmealforpredialysischronickidneydiseasepatientsarandomizedcontrolledtrial
AT chungmuchi efficacyandsafetyofahighenergylowproteinformulareplacementmealforpredialysischronickidneydiseasepatientsarandomizedcontrolledtrial
AT huangshihting efficacyandsafetyofahighenergylowproteinformulareplacementmealforpredialysischronickidneydiseasepatientsarandomizedcontrolledtrial
AT chenyunyu efficacyandsafetyofahighenergylowproteinformulareplacementmealforpredialysischronickidneydiseasepatientsarandomizedcontrolledtrial
AT chenchenghsu efficacyandsafetyofahighenergylowproteinformulareplacementmealforpredialysischronickidneydiseasepatientsarandomizedcontrolledtrial